

# Pablo Cabral

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1122138/publications.pdf>

Version: 2024-02-01

44  
papers

579  
citations

687363

13  
h-index

677142

22  
g-index

46  
all docs

46  
docs citations

46  
times ranked

784  
citing authors

#	ARTICLE	IF	CITATIONS
1	Discovery of Potent EGFR Inhibitors through the Incorporation of a 3D Aromatic Boron-Rich Cluster into the 4-Anilinoquinazoline Scaffold: Potential Drugs for Glioma Treatment. <i>Chemistry - A European Journal</i> , 2018, 24, 3122-3126.	3.3	54
2	Small-Molecule Kinase Inhibitors Loaded Boron Cluster as Hybrid Agents for Glioma Cell Targeting Therapy. <i>Chemistry - A European Journal</i> , 2017, 23, 9233-9238.	3.3	50
3	<sup>99m</sup> Tc-bioorthogonal click chemistry reagent for in vivo pretargeted imaging. <i>Bioorganic and Medicinal Chemistry</i> , 2016, 24, 1209-1215.	3.0	43
4	Development of new PTK7-targeting aptamer-fluorescent and -radiolabelled probes for evaluation as molecular imaging agents: Lymphoma and melanoma in vivo proof of concept. <i>Bioorganic and Medicinal Chemistry</i> , 2017, 25, 1163-1171.	3.0	41
5	In vitro and in vivo uptake studies of PAMAM G4.5 dendrimers in breast cancer. <i>Journal of Nanobiotechnology</i> , 2016, 14, 45.	9.1	37
6	Bimodal Therapeutic Agents Against Glioblastoma, One of the Most Lethal Forms of Cancer. <i>Chemistry - A European Journal</i> , 2020, 26, 14335-14340.	3.3	34
7	Evaluation of <sup>99m</sup> Tc-glucarate as a breast cancer imaging agent in a xenograft animal model. <i>Nuclear Medicine and Biology</i> , 2011, 38, 255-260.	0.6	26
8	Development of <sup>99m</sup> Tc(CO) <sub>3</sub> -dendrimer-FITC for cancer imaging. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2011, 21, 5598-5601.	2.2	20
9	Biological evaluation of glucose and deoxyglucose derivatives radiolabeled with [ <sup>99m</sup> Tc(CO) <sub>3</sub> (H <sub>2</sub> O) <sub>3</sub> ] <sup>+</sup> core as potential melanoma imaging agents. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2011, 21, 7102-7106.	2.2	19
10	[ <sup>99m</sup> Tc(CO) <sub>3</sub> ]-Radiolabeled Bevacizumab: In vitro and in vivo Evaluation in a Melanoma Model. <i>Oncology</i> , 2013, 84, 200-209.	1.9	18
11	Carboranyl anilinoquinazoline EGFR-inhibitors: toward a lead-to-candidate™ stage in the drug-development pipeline. <i>Future Medicinal Chemistry</i> , 2019, 11, 2273-2285.	2.3	17
12	Sgc8-c Aptamer as a Potential Theranostic Agent for Hemato-Oncological Malignancies. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2020, 35, 262-270.	1.0	17
13	Increasing the potency of neutralizing single-domain antibodies by functionalization with a CD11b/CD18 binding domain. <i>MAbs</i> , 2015, 7, 820-828.	5.2	15
14	Technetium-99m- or Cy7-Labeled Rituximab as an Imaging Agent for Non-Hodgkin Lymphoma. <i>Oncology</i> , 2017, 92, 229-242.	1.9	15
15	Cell uptake mechanisms of PAMAM G4-FITC dendrimer in human myometrial cells. <i>Journal of Nanoparticle Research</i> , 2013, 15, 1.	1.9	14
16	Synthesis of hydrophilic HYNIC-[1,2,4,5]tetrazine conjugates and their use in antibody pretargeting with <sup>99m</sup> Tc. <i>Organic and Biomolecular Chemistry</i> , 2018, 16, 5275-5285.	2.8	14
17	Microwave-assisted Synthesis of HYNIC Protected Analogue for <sup>99m</sup> Tc Labeled Antibody. <i>Current Radiopharmaceuticals</i> , 2014, 7, 84-90.	0.8	13
18	Glucosylated Polymeric Micelles Actively Target a Breast Cancer Model. <i>Advanced Therapeutics</i> , 2021, 4, .	3.2	12

#	ARTICLE	IF	CITATIONS
19	Technetium glucose complexes as potential cancer imaging agents. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2015, 25, 4254-4259.	2.2	10
20	Derivatizations of Sgc8â€ aptamer to prepare metallic radiopharmaceuticals as imaging diagnostic agents: Syntheses, isolations, and physicochemical characterizations. <i>Chemical Biology and Drug Design</i> , 2018, 91, 747-755.	3.2	10
21	T908 Polymeric Micelles Improved the Uptake of Sgc8-c Aptamer Probe in Tumor-Bearing Mice: A Co-Association Study between the Probe and Preformed Nanostructures. <i>Pharmaceuticals</i> , 2022, 15, 15.	3.8	10
22	Radiopharmaceuticals in Tumor Hypoxia Imaging: A Review Focused on Medicinal Chemistry Aspects. <i>Anti-Cancer Agents in Medicinal Chemistry</i> , 2017, 17, 318-332.	1.7	9
23	Preparation and Primary Bioevaluation of <sup>99m</sup> Tc-labeled-1-thio-Î²-D-Glucose as Melanoma Targeting Agent. <i>Current Radiopharmaceuticals</i> , 2011, 4, 355-360.	0.8	9
24	Evaluation of Patients with Head and Neck Cancer by Means of <sup>99m</sup> Tc-Glucarate. <i>Journal of Nuclear Medicine Technology</i> , 2009, 37, 229-232.	0.8	7
25	Synthesis and Evaluation of <sup>99m</sup> Tc Chelate-conjugated Bevacizumab. <i>Current Radiopharmaceuticals</i> , 2013, 6, 12-19.	0.8	7
26	Imaging Radiation Doses and Associated Risks and Benefits in Subjects Participating in Breast Cancer Clinical Trials. <i>Oncologist</i> , 2015, 20, 702-712.	3.7	6
27	<sup>99m</sup> Technetium- or Cy7-Labeled Fab(Tocilizumab) as Potential Multiple Myeloma Imaging Agents. <i>Anti-Cancer Agents in Medicinal Chemistry</i> , 2021, 21, 1883-1893.	1.7	6
28	<sup>177</sup> Lu-DOTA-Bevacizumab: Radioimmunotherapy Agent for Melanoma. <i>Current Radiopharmaceuticals</i> , 2017, 10, 21-28.	0.8	6
29	Evaluation of chromosomal aberrations induced by <sup>188</sup> Re-dendrimer nanosystem on B16f1 melanoma cells. <i>International Journal of Radiation Biology</i> , 2018, 94, 664-670.	1.8	5
30	Selective Hypoxiaâ€Cytotoxin <sup>7</sup> â€Fluoroâ€Aminophenazine 5,10â€Dioxide: Toward â€Candidateâ€Drugâ€Stage in the Drugâ€Development Pipeline. <i>ChemistrySelect</i> , 2019, 4, 9396-9402.	1.5	5
31	Mannose receptor 1 expression does not determine the uptake of high-density mannose dendrimers by activated macrophages populations. <i>PLoS ONE</i> , 2020, 15, e0240455.	2.5	5
32	<sup>99m</sup> Tc-Labeled Bevacizumab via HYNIC for Imaging of Melanoma. <i>Journal of Analytical Oncology</i> , 2014, 3, .	0.1	5
33	[ <sup>99m</sup> Tc(CO) <sub>3</sub> ] <sup>+</sup> and [ <sup>99m</sup> TcO <sub>2</sub> ] <sup>+</sup> ; Radiolabeled Cyclic Melanotropin Peptides for Melanoma SPECT Imaging. <i>Current Radiopharmaceuticals</i> , 2014, 7, 63-74.	0.8	4
34	In Vitro and In Vivo Evaluation of [ <sup>99m</sup> Tc(CO) <sub>3</sub> ]-Radiolabeled ErbB-2-Targeting Peptides for Breast Carcinoma Imaging. <i>Current Radiopharmaceuticals</i> , 2010, 3, 308-321.	0.8	4
35	Synthesis of <sup>99m</sup> Tc-Nimotuzumab with Tricarbonyl Ion: in vitro and in vivo Studies. <i>Current Radiopharmaceuticals</i> , 2012, 5, 59-64.	0.8	2
36	<sup>99m</sup> Tc Stearyl 6-(benzylidenehydrazinyl) nicotinamide Liposomes as Tumor Permeability Evaluation Tracer. <i>AAPS PharmSciTech</i> , 2021, 22, 115.	3.3	2

#	ARTICLE	IF	CITATIONS
37	Development and Evaluation of 2-Amino-7-Fluorophenazine 5,10-Dioxide Polymeric Micelles as Antitumoral Agents for 4T1 Breast Cancer. <i>Polymers</i> , 2022, 14, 71.	4.5	2
38	Radio- and Fluorescent-Labeling of Rituximab Based on the Inverse Electron Demand Diels-Alder Reaction. <i>ChemistrySelect</i> , 2021, 6, 1894-1899.	1.5	1
39	The Effect of A Hexanoic Acid Linker Insertion on the Pharmacokinetics and Tumor Targeting Properties of the Melanoma Imaging Agent <sup>99m</sup> Tc-HYNIC-cycMSH. <i>Anti-Cancer Agents in Medicinal Chemistry</i> , 2017, 17, 1144-1152.	1.7	1
40	Microwave-assisted solid-phase synthesis of nicotinyl hydrazones for use in radiochemistry of technetium-99m. <i>Arkivoc</i> , 2018, 2018, 29-38.	0.5	1
41	<sup>99m</sup> Tc-Technetium-Tocilizumab Fragments As Molecular Imaging Agent for Multiple Myeloma. <i>Blood</i> , 2015, 126, 4214-4214.	1.4	1
42	Cy7-Tocilizumab/Fab(Tocilizumab): Near Infrared Fluorescence In Vivo Imaging of Multiple Myeloma. <i>Blood</i> , 2018, 132, 5621-5621.	1.4	1
43	<sup>99m</sup> Tc radiolabeled archaeosomes as a potential melanoma imaging agent. <i>Proceedings of Anticancer Research</i> , 2018, 2, .	0.1	0
44	Potencial empleo del heptapéptido ATWLPPR como agente de imagen molecular del angiogénesis tumoral. <i>Salud Militar</i> , 2019, 38, .	0.0	0